Publicaciones en las que colabora con Bruno K. Rodiño Janeiro (19)

2016

  1. Change of concept about the regulation of angiotensin II-induced monocyte chemoattractant protein-1 production in human endothelial cells

    Vascular Pharmacology, Vol. 80, pp. 20-34

  2. Endothelial progenitor cells mobilisation after percutaneous coronary intervention: a pilot study

    British Journal of Biomedical Science, Vol. 73, Núm. 4, pp. 194-200

2015

  1. Advanced glycation end-products as long-term predictors of death and reinfarction after an acute coronary syndrome

    Biomarkers in Medicine, Vol. 9, Núm. 3, pp. 209-216

  2. Glycated human serum albumin induces NF-κB activation and endothelial nitric oxide synthase uncoupling in human umbilical vein endothelial cells

    Journal of Diabetes and its Complications, Vol. 29, Núm. 8, pp. 984-992

  3. Key structural and functional differences between early and advanced glycation products

    Journal of Molecular Endocrinology, Vol. 56, Núm. 1, pp. 23-37

2013

  1. Current status of NADPH oxidase researchin cardiovascular pharmacology

    Vascular Health and Risk Management, Vol. 9, Núm. 1, pp. 401-428

  2. Differential clinical characteristics and prognosis of intraventricular conduction defects in patients with chronic heart failure

    European Journal of Heart Failure, Vol. 15, Núm. 8, pp. 877-884

  3. Fluorescent Advanced Glycation End Products and Their Soluble Receptor: The Birth of New Plasmatic Biomarkers for Risk Stratification of Acute Coronary Syndrome

    PLoS ONE, Vol. 8, Núm. 9

  4. Statins modulate feedback regulation mechanisms between advanced glycation end-products and C-reactive protein: Evidence in patients with acute myocardial infarction

    European Journal of Pharmaceutical Sciences, Vol. 49, Núm. 4, pp. 512-518

2012

  1. Advanced glycation end products: A mysterious shadow beyond the relationship between HbA1c and atrial fibrillation

    International Journal of Cardiology, Vol. 157, Núm. 3, pp. 441

  2. Evidence for a role of advanced glycation end products in atrial fibrillation

    International Journal of Cardiology, Vol. 157, Núm. 3, pp. 397-402

  3. Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report

    Cardiovascular Diabetology, Vol. 11

  4. Procyanidins from grape pomace are suitable inhibitors of human endothelial NADPH oxidase

    Journal of Cellular Biochemistry, Vol. 113, Núm. 4, pp. 1386-1396

2011

  1. Productos de glicación avanzada: nuevo marcador de disfunción renal en pacientes con insuficiencia cardíaca crónica

    Medicina Clinica, Vol. 136, Núm. 12, pp. 513-521

  2. Receptor for advanced glycation end-products expression in subcutaneous adipose tissue is related to coronary artery disease

    European Journal of Endocrinology, Vol. 164, Núm. 4, pp. 529-537

  3. Relation of soluble receptor for advanced glycation end products to predict mortality in patients with chronic heart failure independently of seattle heart failure score

    American Journal of Cardiology, Vol. 107, Núm. 6, pp. 938-944

2010

  1. Glycated albumin, a precursor of advanced glycation end-products, up-regulates NADPH oxidase and enhances oxidative stress in human endothelial cells: Molecular correlate of diabetic vasculopathy

    Diabetes/Metabolism Research and Reviews, Vol. 26, Núm. 7, pp. 550-558

  2. Pravastatin counteracts angiotensin II-induced upregulation and activation of nadph oxidase at plasma membrane of human endothelial cells

    Journal of Cardiovascular Pharmacology, Vol. 55, Núm. 2, pp. 203-212

  3. Soluble receptor of advanced glycation end products levels are related to ischaemic aetiology and extent of coronary disease in chronic heart failure patients, independent of advanced glycation end products levels

    European Journal of Heart Failure, Vol. 12, Núm. 10, pp. 1092-1100